title: Therapy-related myeloid neoplasm with bone marrow involvement, myelosarcoma, and a t(8;16)(p11.2;p13.3)-a case report.
abstract: Therapy-related leukemia is a well-documented complication of conventional therapy for cancer. Therapy-related acute myeloid leukemia (t-AML) is grouped along with therapy-related myelodysplastic syndrome (t-MDS) and therapy-related myelodysplastic syndrome/myeloproliferative neoplasms (t-MDS/MPNs) as therapy-related myeloid neoplasms (t-MNs) by the 2008 World Health Organization classification system. Therapy-related myeloid neoplasms differ clinically from their de novo counterparts in terms of response to therapy, aggressiveness of disease, and associated poor prognosis. The occurrence of extramedullary myeloid sarcomas with bone marrow involvement has been shown to be a poor prognostic indicator for patients with t-MN. The karyotype of leukemic blasts has also been reported to have a significant impact in t-MN and may predict survival and outcomes in patients. The t(8;16)(p11.2;p13.3) is a rare, balanced translocation that is frequently associated with the M4/M5 subtype of de novo acute myeloid leukemia. It has also been reported in patients with t-MN, typically in those with poor outcomes. Here we report a case of t-MN with myeloid sarcoma and bone marrow involvement in an adult patient with a karyotype of 47,XY,t(8;16)(p11.2;p13.3),+21 after rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy for follicular lymphoma.
authors.affiliation: Division of Diagnostic Genomics, Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA.
authors.forename: Sujata
authors.initials: S
authors.lastname: Chakraborty
authors.affiliation: Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.
authors.forename: Julia
authors.initials: J
authors.lastname: Adams
authors.affiliation: Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.
authors.forename: Mehdi
authors.initials: M
authors.lastname: Nassiri
authors.affiliation: Division of Diagnostic Genomics, Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA; Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA. Electronic address: ghvance@iu.edu.
authors.forename: Gail H
authors.initials: GH
authors.lastname: Vance
mesh_terms: D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002885:Chromosomes, Human, Pair 16; D002898:Chromosomes, Human, Pair 8; D003520:Cyclophosphamide / Q000627:therapeutic use; D020732:Cytogenetic Analysis; D004317:Doxorubicin / Q000627:therapeutic use; D006801:Humans; D008224:Lymphoma, Follicular / Q000188:drug therapy; D008297:Male; D016609:Neoplasms, Second Primary / Q000235:genetics* / Q000473:pathology; D011241:Prednisone / Q000627:therapeutic use; D000069283:Rituximab; D023981:Sarcoma, Myeloid / Q000235:genetics* / Q000473:pathology; D014178:Translocation, Genetic; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; C571759:R-CHOP protocol; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone
keywords: Therapy-related myeloid neoplasms; acute myeloid leukemia; cytogenetics; myeloid sarcoma; t(8;16)(p11.2;p13.3)